FI4098256T3 - Annosteluohjelma s1p-reseptorin agonistille - Google Patents

Annosteluohjelma s1p-reseptorin agonistille Download PDF

Info

Publication number
FI4098256T3
FI4098256T3 FIEP22187007.4T FI22187007T FI4098256T3 FI 4098256 T3 FI4098256 T3 FI 4098256T3 FI 22187007 T FI22187007 T FI 22187007T FI 4098256 T3 FI4098256 T3 FI 4098256T3
Authority
FI
Finland
Prior art keywords
agonist
daily dose
dose
usual daily
receptor modulator
Prior art date
Application number
FIEP22187007.4T
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Olivier David
Michael Looby
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4098256(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI4098256T3 publication Critical patent/FI4098256T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (2)

ANNOSTELUOHJELMA S1P-RESEPTORIN AGONISTILLE PATENTTIVAATIMUKSET
1. S1P-reseptorin modulaattorin tai agonistin, joka signaloi agonistina yhdessä tai useammassa S1P-reseptorissa ja joka on selektiivinen S1P:-reseptorille ja joka indusoi negatiivisen kronotroop- —pisen vaikutuksen sydämen sykkeessä, käyttö lääkkeen valmistamisessa autoimmuunisairauden hoitamiseksi, joka on valittu pesäkekovettumataudista, polymyosiitista, lupusnefriitistä, nivelreu- masta, tulehduksellisesta suolistosairaudesta ja psoriaasiksesta, jolloin mainittua lääkettä anne- taan niin, että hoidon aloitusjakson aikana annos on matalampi kuin tavanomainen päivittäisannos ja annosta nostetaan asteittain tai vain kerran, kunnes saavutetaan tavanomainen päivittäisannos, ja sen jälkeen hoitoa jatketaan mainitun S1P-reseptorin modulaattorin tai agonistin tavanomaisella päivittäisannoksella, jossa hoidon sen aloitusjakson pituus, jonka aikana S1P-reseptorin modulaat- toria tai agonistia annetaan tavanomaista päivittäisannosta matalammalla annoksella, on 7 päivää niin, että päivänä, jolloin annetaan mainitun S1P-reseptorin modulaattorin tai agonistin tavanomai- nen päivittäisannos, lasku sydämen sykkeessä on rajoittunut noin 2 lyönnillä/min tai vähemmän.
2. S1P-reseptorin modulaattori tai agonisti, joka signaloi agonistina yhdessä tai useammassa S1P- reseptorissa ja joka on selektiivinen S1P1-reseptorille ja joka indusoi negatiivisen kronotrooppisen vaikutuksen sydämen sykkeessä, käytettäväksi autoimmuunisairauden hoitamisessa, joka on valit- tu pesäkekovettumataudista, polymyosiitista, lupusnefriitistä, nivelreumasta, tulehduksellisesta suolistosairaudesta ja psoriaasiksesta, jolloin mainittua lääkettä annetaan niin, että hoidon aloitus- — jakson aikana annos on matalampi kuin tavanomainen päivittäisannos ja annosta nostetaan asteit- tain tai vain kerran, kunnes saavutetaan tavanomainen päivittäisannos, ja sen jälkeen hoitoa jatke- taan mainitun S1P-reseptorin modulaattorin tai agonistin tavanomaisella päivittäisannoksella, jossa hoidon sen aloitusjakson pituus, jonka aikana S1P-reseptorin modulaattoria tai agonistia annetaan tavanomaista päivittäisannosta matalammalla annoksella, on 7 päivää niin, että päivänä, jolloin — annetaan mainitun S1P-reseptorin modulaattorin tai agonistin tavanomainen päivittäisannos, lasku sydämen sykkeessä on rajoittunut noin 2 lyönnillä/min tai vähemmän.
FIEP22187007.4T 2008-12-22 2009-12-21 Annosteluohjelma s1p-reseptorin agonistille FI4098256T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
FI4098256T3 true FI4098256T3 (fi) 2025-03-31

Family

ID=41667217

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP22187007.4T FI4098256T3 (fi) 2008-12-22 2009-12-21 Annosteluohjelma s1p-reseptorin agonistille
FIC20253002C FIC20253002I1 (fi) 2008-12-22 2025-05-23 Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIC20253002C FIC20253002I1 (fi) 2008-12-22 2025-05-23 Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola

Country Status (43)

Country Link
US (12) US20100160259A1 (fi)
EP (7) EP4098256B9 (fi)
JP (7) JP2012513401A (fi)
KR (1) KR101347919B1 (fi)
CN (1) CN102264359A (fi)
AR (1) AR074826A1 (fi)
AU (1) AU2009330176C9 (fi)
BR (1) BRPI0923500A2 (fi)
CA (1) CA2747802C (fi)
CL (2) CL2011001529A1 (fi)
CO (1) CO6390117A2 (fi)
CR (1) CR20110274A (fi)
CU (1) CU20110136A7 (fi)
CY (5) CY1116990T1 (fi)
DK (4) DK3409274T3 (fi)
EA (1) EA201100978A1 (fi)
EC (1) ECSP11011222A (fi)
ES (4) ES2760607T3 (fi)
FI (2) FI4098256T3 (fi)
FR (2) FR20C1060I1 (fi)
HN (1) HN2011001759A (fi)
HR (4) HRP20250568T1 (fi)
HU (6) HUE026869T2 (fi)
IL (3) IL213170A0 (fi)
LT (5) LT3453387T (fi)
LU (1) LUC00183I2 (fi)
MA (1) MA32981B1 (fi)
ME (2) ME03802B (fi)
MX (3) MX2011006623A (fi)
NO (1) NO2020038I1 (fi)
NZ (1) NZ593065A (fi)
PE (1) PE20120337A1 (fi)
PL (4) PL4098256T3 (fi)
PT (4) PT3409274T (fi)
RS (3) RS66784B9 (fi)
SG (1) SG171404A1 (fi)
SI (4) SI2379067T1 (fi)
SM (2) SMT202000441T1 (fi)
TN (1) TN2011000272A1 (fi)
TW (1) TW201028143A (fi)
UY (1) UY32352A (fi)
WO (1) WO2010075239A1 (fi)
ZA (2) ZA201103863B (fi)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
US20100160259A1 (en) 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
EP3831371A1 (en) 2009-09-29 2021-06-09 Novartis AG Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011138398A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
HUE050733T2 (hu) 2012-08-17 2021-01-28 Actelion Pharmaceuticals Ltd Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
HUE057865T2 (hu) 2014-12-11 2022-06-28 Actelion Pharmaceuticals Ltd A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
AU2021228371A1 (en) * 2020-02-28 2022-10-13 Akaal Pharma Pty Ltd S1P receptor modulators
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP5227492B2 (ja) 2002-05-16 2013-07-03 ノバルティス アーゲー 癌におけるedgレセプター結合剤の使用
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2384749A1 (en) * 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
CN101541227B (zh) * 2005-02-10 2013-06-05 G.I.视频有限公司 用于带导向元件的胃肠工具的前进技术
WO2009048993A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
CA2716448A1 (en) * 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
WO2009155475A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
US20100160259A1 (en) 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
MX367667B (es) * 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.

Also Published As

Publication number Publication date
PL2379067T3 (pl) 2016-02-29
AU2009330176C9 (en) 2017-01-05
CY2020036I2 (el) 2021-06-25
US20180289638A1 (en) 2018-10-11
LTPA2025520I1 (fi) 2025-06-25
ME03802B (me) 2021-04-20
RS60666B1 (sr) 2020-09-30
DK4098256T5 (da) 2025-07-21
JP2024129030A (ja) 2024-09-26
HUE048717T4 (hu) 2022-02-28
PT4098256T (pt) 2025-04-10
US20170189353A1 (en) 2017-07-06
JP2022103194A (ja) 2022-07-07
SMT202000054T1 (it) 2020-03-13
MX385959B (es) 2025-03-18
CY2025012I1 (el) 2026-02-25
EP3120844A1 (en) 2017-01-25
SG171404A1 (en) 2011-07-28
CY1122812T1 (el) 2021-05-05
CO6390117A2 (es) 2012-02-29
AU2009330176B2 (en) 2014-03-06
PE20120337A1 (es) 2012-04-24
MX2011006623A (es) 2011-07-12
RS66784B9 (sr) 2025-08-29
HUS2500026I1 (hu) 2025-07-28
ZA201103863B (en) 2012-10-31
BRPI0923500A2 (pt) 2018-05-29
IL278914A (en) 2021-01-31
US20140148415A1 (en) 2014-05-29
JP7329965B2 (ja) 2023-08-21
HRP20192175T1 (hr) 2020-03-20
LT3453387T (lt) 2020-08-25
DK3453387T3 (da) 2020-08-10
DK4098256T3 (da) 2025-04-22
NZ593065A (en) 2012-11-30
HUE026869T2 (en) 2016-08-29
AU2009330176A1 (en) 2011-07-07
JP2014144970A (ja) 2014-08-14
ES2760607T3 (es) 2020-05-14
EP3409274B1 (en) 2019-11-20
RS59857B1 (sr) 2020-02-28
PT2379067E (pt) 2015-12-23
EP2379067B1 (en) 2015-09-02
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
AR074826A1 (es) 2011-02-16
MX2021010759A (es) 2022-07-19
SI2379067T1 (sl) 2016-01-29
CL2011001529A1 (es) 2012-02-24
KR20110096175A (ko) 2011-08-29
RS66784B1 (sr) 2025-06-30
HRP20201167T1 (hr) 2020-12-11
SMT202000441T1 (it) 2020-09-10
LUC00183I2 (fi) 2024-07-01
HRP20151190T1 (hr) 2016-01-01
US20110257133A1 (en) 2011-10-20
EP3453387A1 (en) 2019-03-13
ES2552823T3 (es) 2015-12-02
HRP20250568T1 (hr) 2025-07-04
HUE052048T2 (hu) 2021-04-28
CL2013001558A1 (es) 2013-10-25
CY1123255T1 (el) 2021-10-29
FIC20253002I1 (fi) 2025-05-23
FR25C1012I1 (fr) 2025-06-13
CY2025012I2 (el) 2026-02-25
HUE048717T2 (hu) 2020-08-28
UY32352A (es) 2010-07-30
EP3453387B1 (en) 2020-06-03
US20250262171A1 (en) 2025-08-21
NO2020038I1 (no) 2020-11-18
LTPA2020005I1 (lt) 2020-12-10
TN2011000272A1 (en) 2012-12-17
CY2020036I1 (el) 2021-03-12
CN102264359A (zh) 2011-11-30
SI3409274T1 (sl) 2020-03-31
EP4098256A1 (en) 2022-12-07
SI4098256T1 (sl) 2025-06-30
US20160081949A1 (en) 2016-03-24
EP4098256B9 (en) 2025-06-18
US20140066657A1 (en) 2014-03-06
EP2379067A1 (en) 2011-10-26
WO2010075239A1 (en) 2010-07-01
JP2012513401A (ja) 2012-06-14
ES2810823T3 (es) 2021-03-09
EA201100978A1 (ru) 2012-01-30
EP4098256B1 (en) 2025-02-26
EP3677260A1 (en) 2020-07-08
EP2907511A1 (en) 2015-08-19
IL274756A (en) 2020-07-30
LT4098256T (lt) 2025-06-10
HUS2000046I1 (hu) 2020-12-28
IL213170A0 (en) 2011-07-31
PL3409274T3 (pl) 2020-06-01
FR20C1060I1 (fr) 2020-12-25
US20190091180A1 (en) 2019-03-28
MA32981B1 (fr) 2012-01-02
JP2019167360A (ja) 2019-10-03
US20100160259A1 (en) 2010-06-24
KR101347919B1 (ko) 2014-01-07
PL3453387T3 (pl) 2020-11-02
EP3409274A1 (en) 2018-12-05
HUE071189T2 (hu) 2025-08-28
JP2016135752A (ja) 2016-07-28
SI3453387T1 (sl) 2020-10-30
JP2017141238A (ja) 2017-08-17
ZA201205942B (en) 2013-03-27
DK2379067T3 (en) 2015-12-07
ECSP11011222A (es) 2011-08-31
CR20110274A (es) 2011-07-19
TW201028143A (en) 2010-08-01
AU2009330176C1 (en) 2016-12-08
ES3017254T3 (en) 2025-05-12
PT3453387T (pt) 2020-08-11
CA2747802C (en) 2021-02-09
DK3409274T3 (da) 2019-12-16
US20200330407A1 (en) 2020-10-22
PL4098256T3 (pl) 2025-06-09
ME03594B (me) 2020-07-20
HN2011001759A (es) 2013-11-26
CA2747802A1 (en) 2010-07-01
CU20110136A7 (es) 2012-01-31
US20160263061A1 (en) 2016-09-15
PT3409274T (pt) 2019-12-17
CY1116990T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
HRP20250568T1 (hr) Režim doziranja agonista s1p receptora
NZ588505A (en) Dosing regimen for a selective S1P1 receptor agonist (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one
JP2016528301A5 (fi)
RU2010143864A (ru) Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
NZ589445A (en) Rasagiline for parkinson's disease modification
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
RU2014109074A (ru) ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
HRP20171570T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
RU2012141951A (ru) Курс лечения с использованием агониста рецептора sip
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ714963A (en) Compositions and methods for treating anemia
JP2016185995A5 (fi)
JP2013541583A5 (fi)
WO2008030830A3 (en) Sustained-release composition and method of use thereof
RU2013127420A (ru) Способы уменьшения психогенного или компульсивного переедания
ME02474B (me) Terapijski režimi
JP2018138596A5 (fi)
RU2015141151A (ru) Идентификация реакции пациентов на введение модулятора рецепторов s1p
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
FI3188727T3 (fi) Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi
JP2009544690A5 (fi)